Rodriguez AJ, Ernst MT, Nybo M, et al. - Since the cardiovascular (CV) safety of oral bisphosphonates (oBP) is unclear, researchers conducted this cohort study to assess the risk of CV events in oBP users referred for bone mineral density (BMD) testing vs matched controls. The sample consisted of individuals aged ≥ 45 years who were referred for BMD testing. Findings revealed that there were 2,565 oBP users (82.6% women) and 4,568 (82.3% women) propensity score-matched controls. Oral BP users experienced a 33% reduction in the risk of CV events. This observational real-world research adds to a growing body of evidence for cardio-protection by oBP which warrants testing in a randomized setting.